Surfing the MASH Tsunami
Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Jörn Schattenberg, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green and a global group of Key Opinion Leaders and patient advocates as they discuss key issues in Fatty Liver disease, including epidemiology, drug development, clinical pathways, non-invasive testing, health economics and regulatory issues, from their own unique perspectives on the Surfing the MASH Tsunami podcast. #MASH #MAFLD #FattyLiver #livertwitter #AASLD #GlobalLiver #NoNASH #EASL
Surfing the MASH Tsunami
S2-E16.2 - Future Directions for NASH Cost-Effectiveness Research
•
HEP Dynamics
•
Season 2
•
Episode 16
Mazen Noureddin and Stephen Harrison discuss future directions cost-effectiveness research in and outside the U.S. might take, while the Surfers consider the implications.
In response to questions from Roger Green and Stephen Harrison, this conversation starts by exploring where cost-effectiveness research might head next. Louise Campbell provides context from other recent studies and Stephen asks about the impact of expanding these models to encompass costs of hepatocellular carcinoma. At the end of this conversation, the group considers how public explanation of expanded testing might sit with patients and other stakeholders.
In response to questions from Roger Green and Stephen Harrison, this conversation starts by exploring where cost-effectiveness research might head next. Louise Campbell provides context from other recent studies and Stephen asks about the impact of expanding these models to encompass costs of hepatocellular carcinoma. At the end of this conversation, the group considers how public explanation of expanded testing might sit with patients and other stakeholders.